Journal Home
Search for

Volume 28, Issue 3, Pages 255-263 (April 2005)


View previous. 8 of 12 View next.

Factors associated with 12 months continuous heroin abstinence: findings from the Australian Treatment Outcome Study (ATOS)

Shane Darke, Ph.D.aCorresponding Author Informationemail address, Joanne Ross, Ph.D.a, Maree Teesson, Ph.D.a, Robert Ali, M.B.B.S.b, Richard Cooke, B.A. Honsb, Allison Ritter, Ph.D.c, Michael Lynskey, Ph.D.d

Received 19 July 2004; received in revised form 10 December 2004; accepted 11 January 2005.

Abstract 

Aims: To determine the role of treatment and client characteristics associated with the achievement of continuous heroin abstinence. Design: Longitudinal cohort study. Setting: Sydney and Adelaide, Australia. Participants: 570 heroin users re-interviewed at 12 month follow-up for the Australian Treatment Outcome Study (ATOS). Findings: Continuous heroin abstinence was reported by 14% of participants. Continuous abstinence was associated with no previous treatment history, having entered treatment at baseline, and cumulative treatment exposure over the follow-up period. Longer retention times in index maintenance and residential rehabilitation treatments, but not detoxifications, were most associated with abstinence. At baseline, abstinent participants were more likely to have been classified as treatment ready, or to have used heroin less frequently; and less likely to have been daily injectors, using cocaine or criminally involved. Conclusions: Approximately 14% of ATOS participants achieved continuous heroin abstinence over 12 months. Such an achievement was strongly associated with a longer “dose” of treatment, and with more treatment stability over the follow-up period.

a National Drug and Alcohol Research Centre, University of New South Wales, NSW, Australia

b Drug and Alcohol Services Council, South Australia, Australia

c Turning Point Drug and Alcohol Service, Victoria, Australia

d Department of Psychiatry, Washington University School of Medicine, St Louis, MO, USA

Corresponding Author InformationCorresponding author. National Drug and Alcohol Research Centre, University of New South Wales, NSW, 2052, Australia. Tel.: +1 61 2 9385 0333.

PII: S0740-5472(05)00018-8

doi:10.1016/j.jsat.2005.01.006


View previous. 8 of 12 View next.